Article
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.
Cancer cell - 1 Oct 2003
Stojdl David F, Lichty Brian D, tenOever Benjamin R, Paterson Jennifer M, Power Anthony T, Knowles Shane, Marius Ricardo, Reynard Jennifer, Poliquin Laurent, Atkins Harold, Brown Earl G, Durbin Russell K, Durbin Joan E, Hiscott John, Bell John C
Abstract excerpt
Ideally, an oncolytic virus will replicate preferentially in malignant cells, have the ability to treat disseminated metastases, and ultimately be cleared by the patient. Here we present evidence that the attenuated vesicular stomatitis strains, AV1 and AV2, embody all of these traits. We uncover the mechanism by which these mutants are selectively attenuated in interferon-responsive cells while remaining highly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.